This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.
NIHR HSRIC. Nivolumab for follicular non-Hodgkin lymphoma ─ third line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016
Lymphoma is a cancer of the lymphatic system, which is part of the immune system. It contains cells called lymphocytes that fight infections. Follicular lymphoma is the second most common type of non-Hodgkin lymphoma. It often progresses slowly, with patients showing no symptoms for many years.
Nivolumab is a new antibody drug for the treatment of follicular lymphoma that is delivered straight into the bloodstream via a drip. Some studies have suggested that this drug may be helpful for people with follicular lymphoma whose disease has returned after previous treatments have stopped working.
If nivolumab is licensed for use in the UK, it could be a new treatment option for follicular lymphoma that may improve survival.
Subject indexing assigned by CRD
Antibodies, Monoclonal; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin
Country of organisation
An English language summary is available.
Address for correspondence
NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: email@example.com
Date abstract record published